Search

Your search keyword '"Cruz‐Leal, Yoelys"' showing total 30 results
Start Over Author "Cruz‐Leal, Yoelys"
30 results on '"Cruz‐Leal, Yoelys"'

1. Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized murine model of ITP

Author

Gil Gonzalez, Lazaro, Won, Kevin D., Tawhidi, Zoya, Cummins, Emma, Cruz-Leal, Yoelys, Tundidor Cabado, Yaima, Sachs, Ulrich J., Norris, Peter A. A., Shan, Yuexin, Bhakta, Varsha, Li, Janessa, Samudio, Ismael, Silva-Moreno, Begonia, Cerna-Portillo, Liza, Pavon Oro, Alequis, Bergqvist, Peter, Chan, Patrick, Moorehead, Amy, Sholzberg, Michelle, Sheffield, William P., and Lazarus, Alan H.

Published
2024
Full Text
View/download PDF

6. Sticholysins, pore-forming proteins from a marine anemone can induce maturation of dendritic cells through a TLR4 dependent-pathway

Author

Laborde, Rady J., Ishimura, Mayari E., Abreu-Butin, Lianne, Nogueira, Catarina V., Grubaugh, Daniel, Cruz-Leal, Yoelys, Luzardo, María C., Fernández, Audry, Mesa, Circe, Pazos, Fabiola, Álvarez, Carlos, Alonso, María E., Starnbach, Michael N., Higgins, Darren E., Fernández, Luis E., Longo-Maugéri, Ieda M., and Lanio, María E.

Published
2021
Full Text
View/download PDF

9. THP-1 cells transduced with CD16A utilize Fcγ receptor I and III in the phagocytosis of IgG-sensitized human erythrocytes and platelets

Author

Gil Gonzalez, Lazaro, primary, Fernandez-Marrero, Yuniel, additional, Norris, Peter Alan Albert, additional, Tawhidi, Zoya, additional, Shan, Yuexin, additional, Cruz-Leal, Yoelys, additional, Won, Kevin Doyoon, additional, Frias-Boligan, Kayluz, additional, Branch, Donald R., additional, and Lazarus, Alan H., additional

Published
2022
Full Text
View/download PDF

17. Treating murine inflammatory diseases with an anti-erythrocyte antibody

Author

Crow, Andrew R., primary, Kapur, Rick, additional, Koernig, Sandra, additional, Campbell, Ian K., additional, Jen, Chao-Ching, additional, Mott, Patrick J., additional, Marjoram, Danielle, additional, Khan, Ramsha, additional, Kim, Michael, additional, Brasseit, Jennifer, additional, Cruz-Leal, Yoelys, additional, Amash, Alaa, additional, Kahlon, Simrat, additional, Yougbare, Issaka, additional, Ni, Heyu, additional, Zuercher, Adrian W., additional, Käsermann, Fabian, additional, Semple, John W., additional, and Lazarus, Alan H., additional

Published
2019
Full Text
View/download PDF

20. The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes

Author

Cruz-Leal, Yoelys, primary, Grubaugh, Daniel, additional, Nogueira, Catarina V., additional, Lopetegui-González, Isbel, additional, del Valle, Anaixis, additional, Escalona, Felipe, additional, Laborde, Rady J., additional, Alvarez, Carlos, additional, Fernández, Luis E., additional, Starnbach, Michael N., additional, Higgins, Darren E., additional, and Lanio, María E., additional

Published
2018
Full Text
View/download PDF

21. Human Fc gamma receptor IIIA blockade inhibits platelet destruction in a humanized-murine model of ITP

Author

Gonzalez, Lazaro Gil, Won, Kevin Doyoon, Tawhidi, Zoya, Cummins, Emma, Cruz-Leal, Yoelys, Cabado, Yaima Tundidor, Sachs, Ulrich J., Norris, Peter AA, Shan, Yuexin, Bhakta, Varsha, Li, Janessa, Samudio, Ismael, Silva-Moreno, Begonia, Cerna-Portillo, Liza, Oro, Alequis Pavon, Bergqvist, Peter, Chan, Patrick, Moorehead, Amy, Sholzberg, Michelle, Sheffield, William P, and Lazarus, Alan H.

Abstract

✓Human Fcγ receptor III monovalent blocking as a one-armed antibody or albumin fusion protein are effective in a humanized model of ITP.✓The monovalent albumin fusion protein showed no AEs while the Fc impaired one-armed antibody induced minor changes in body temperature.

Published
2024
Full Text
View/download PDF

23. Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response

Author

Laborde, Rady J., primary, Sanchez-Ferras, Oraly, additional, Luzardo, María C., additional, Cruz-Leal, Yoelys, additional, Fernández, Audry, additional, Mesa, Circe, additional, Oliver, Liliana, additional, Canet, Liem, additional, Abreu-Butin, Liane, additional, Nogueira, Catarina V., additional, Tejuca, Mayra, additional, Pazos, Fabiola, additional, Álvarez, Carlos, additional, Alonso, María E., additional, Longo-Maugéri, Ieda M., additional, Starnbach, Michael N., additional, Higgins, Darren E., additional, Fernández, Luis E., additional, and Lanio, María E., additional

Published
2017
Full Text
View/download PDF

25. Erythrocyte Saturation with IgG Is Required for Inducing Antibody-Mediated Immune Suppression and Impacts Both Erythrocyte Clearance and Antigen-Modulation Mechanisms.

Author

Marjoram, Danielle, Cruz-Leal, Yoelys, and Lazarus, Alan H.

Subjects
*ERYTHROCYTES, *IMMUNOGLOBULIN G, *IMMUNOSUPPRESSION, *EPITOPES, *RH factor, *FETAL diseases, *GENETICS
Abstract

Anti-D prevents hemolytic disease of the fetus and newborn, and this mechanism has been referred to as Ab-mediated immune suppression (AMIS). Anti-D, as well as other polyclonal AMIS-inducing Abs, most often induce both epitope masking and erythrocyte clearance mechanisms. We have previously observed that some Abs that successfully induce AMIS effects could be split into those that mediate epitope masking versus those that induce erythrocyte clearance, allowing the ability to analyze these mechanisms separately. In addition, AMIS-inducing activity has recently been shown to induce Ag modulation (Ag loss from the erythrocyte surface). To assess these mechanisms, we immunized mice with transgenic murine RBCs expressing a single Ag protein comprising a recombinant Ag composed of hen egg lysozyme, OVA sequences comprising aa 251-349, and the human Duffy transmembrane protein (HOD-Ag) with serial doses of polyclonal anti-OVA IgG as the AMIS-inducing Ab. The anti-OVA Ab induced AMIS in the absence of apparent epitope masking. AMIS occurred only when the erythrocytes appeared saturated with IgG. This Ab was capable of inducing HOD-RBC clearance, as well as loss of the OVA epitope at doses of Ab that caused AMIS effects. HOD-RBCs also lost reactivity with Abs specific for the hen egg lysozyme and Duffy portions of the Ag consistent with the initiation of Ag modulation and/or trogocytosis mechanisms. These data support the concept that an AMIS-inducing Ab that does not cause epitope masking can induce AMIS effects in a manner consistent with RBC clearance and/or Ag modulation. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

29. An overview of pneumococcal infection and vaccine development discussed at the 5th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD).

Author

Cruz-Leal, Yoelys and Guillén, Gerardo

Subjects
*STREPTOCOCCUS pneumoniae, *GRAM-positive bacteria, *BACTERIAL diseases, *HOST-parasite relationships, *SINUSITIS, *MENINGITIS, *BACTEREMIA, *VACCINATION
Abstract

The article discusses the development of a vaccine for pneomococci (Streptococcus pneumoniae) infections. This Gram-positive bacterium colonizes the upper respiratory tracts and lives in the nasopharynx, where it establishes commensalism. However, a disturbance in the host-pathogen homeostasis can lead to diseases such as acute bacterial sinusitis, meningitis and bacteremia.

Published
2006

30. Study of various presentation forms for a peptide mimetic of Neisseria meningitidis serogroup B capsular polysaccharide.

Author

Garay H, Menéndez T, Cruz-Leal Y, Coizeau E, Noda J, Morera V, Guillén G, Albericio F, and Reyes O

Subjects
Amino Acid Sequence, Animals, Bacterial Capsules chemistry, Dose-Response Relationship, Immunologic, Drug Design, Female, Immunoglobulin G biosynthesis, Immunoglobulin G immunology, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Peptidomimetics chemistry, Protein Multimerization, Protein Structure, Quaternary, Serum Bactericidal Antibody Assay, Antigen Presentation, Bacterial Capsules immunology, Neisseria meningitidis, Serogroup B, Peptidomimetics immunology
Abstract

The formulation of a broadly protective vaccine to prevent the serogroup B Neisseria meningitidis (MenB) disease is still an unmet medical need. We have previously reported the induction of bactericidal and protective antibodies against MenB after immunization of mice with a phage-displayed peptide named 4 L-5. This peptide mimics a capsular polysaccharide (CPS) epitope in MenB. With the aim of developing vaccine formulations that could be used in humans, we evaluate in this study various forms of presentation to the immune system of the 4 L-5 sequence, based on synthetic peptides. We synthesized the following: (i) a linear 4 L-5 peptide, (ii) a multiple antigen peptide containing four copies of the 4 L-5 sequence (named MAP), which was then dimerized, and the product named dimeric MAP, and (iii) a second multiple antigen peptide, in this case with two copies of the 4 L-5 sequence and a copy of a T-helper cell epitope of tetanus toxoid, which was then dimerized and the product named MAP-TT. The linear peptide, the MAP, and the dimeric MAP were conjugated to the carrier protein P64K by different conjugation methods. Plain antigens and antigens coupled to P64K were used to immunize BALB/c mice. Of those variants that gave immunogenic results, MAP-TT rendered the highest levels of specific antipeptide IgG antibodies and serum bactericidal activity. These results can find application in the development of meningococcal vaccine candidates and in peptide-based vaccines strategies.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results